YCJ-01 Full Spectrum cannbis Extract not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Tuberous Sclerosis Complex (TSC)
- Main trialPhase 3
- “1\. To assess treatment efficacy with YCJ-01 by changes in the number of epileptic seizures in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex. 2. To assess the safety of the treatment with YCJ-01 in patients with refractory epilepsy secondary to Tuberous Sclerosis Complex.”In the company’s words, NCT07403266 on ClinicalTrials.gov
Other drugs for Tuberous Sclerosis Complex (TSC)
- EverolimusNovartis · Phase 3
- SVG103Sovargen · Phase 1/2
- AV078Aeovian Pharmaceuticals, Inc. · Phase 2
- RadiprodilGRIN Therapeutics, Inc. · Phase 1/2
- Sapu003SAPU NANO (US) LLC · Phase 1
- CannabidiolJazz Pharmaceuticals · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 1 Jun 2026 | Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026